Mumbai, India (CU)_ Bharat Biotech’s intranasal vaccine has obtained regulatory permission for Phase 2/3 studies, in the midst of a continuing research across the globe to create nasal sprays to battle coronavirus illness. BBV154, an adenoviral intranasal vaccine, is the first of its kind to be tested in humans in India. According to the Ministry of Science and Technology, the Phase 1 experiment in healthy participants aged 18 to 60 years was safe and well tolerated.
According to the ministry, in the preclinical toxicity testing, it was identified that…
